MedTrace Logo

Patient's Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder

NCT00366002 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2008-01-15

No results posted yet for this study

Summary

This study will evaluate safety, efficacy and patient's perception of outcome after treatment with darifenacin (7.5 mg once daily (o.d.) with voluntary increase up to 15 mg o.d.) in patients with OAB who are dissatisfied with prior oxybutynin extended release (ER) or tolterodine extended release (ER) therapy.

Conditions

  • Overactive Bladder (OAB)

Interventions

DRUG

Darifenacin

Darifenacin 7,5 mg tablets once daily with the possibility to up-titrate to 15 mg once daily

Sponsors & Collaborators

  • Procter and Gamble

    collaborator INDUSTRY

  • Novartis

    lead INDUSTRY

Principal Investigators

  • Novartis Pharmaceutical Corporation · NPC

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Completion
2007-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00366002 on ClinicalTrials.gov